S&P 500   5,136.23 (+0.78%)
DOW   39,088.93 (+0.24%)
QQQ   445.55 (+1.49%)
AAPL   179.68 (-0.59%)
MSFT   415.27 (+0.39%)
META   501.97 (+2.42%)
GOOGL   137.79 (-0.48%)
AMZN   178.51 (+0.99%)
TSLA   202.96 (+0.53%)
NVDA   818.80 (+3.50%)
NIO   5.79 (+0.70%)
AMD   200.67 (+4.23%)
BABA   74.62 (+0.80%)
T   17.00 (+0.41%)
F   12.42 (-0.16%)
MU   95.15 (+5.01%)
CGC   3.19 (-3.04%)
GE   158.89 (+1.27%)
DIS   111.94 (+0.32%)
AMC   4.40 (+1.85%)
PFE   26.61 (+0.19%)
PYPL   60.62 (+0.46%)
XOM   105.73 (+1.16%)
S&P 500   5,136.23 (+0.78%)
DOW   39,088.93 (+0.24%)
QQQ   445.55 (+1.49%)
AAPL   179.68 (-0.59%)
MSFT   415.27 (+0.39%)
META   501.97 (+2.42%)
GOOGL   137.79 (-0.48%)
AMZN   178.51 (+0.99%)
TSLA   202.96 (+0.53%)
NVDA   818.80 (+3.50%)
NIO   5.79 (+0.70%)
AMD   200.67 (+4.23%)
BABA   74.62 (+0.80%)
T   17.00 (+0.41%)
F   12.42 (-0.16%)
MU   95.15 (+5.01%)
CGC   3.19 (-3.04%)
GE   158.89 (+1.27%)
DIS   111.94 (+0.32%)
AMC   4.40 (+1.85%)
PFE   26.61 (+0.19%)
PYPL   60.62 (+0.46%)
XOM   105.73 (+1.16%)
S&P 500   5,136.23 (+0.78%)
DOW   39,088.93 (+0.24%)
QQQ   445.55 (+1.49%)
AAPL   179.68 (-0.59%)
MSFT   415.27 (+0.39%)
META   501.97 (+2.42%)
GOOGL   137.79 (-0.48%)
AMZN   178.51 (+0.99%)
TSLA   202.96 (+0.53%)
NVDA   818.80 (+3.50%)
NIO   5.79 (+0.70%)
AMD   200.67 (+4.23%)
BABA   74.62 (+0.80%)
T   17.00 (+0.41%)
F   12.42 (-0.16%)
MU   95.15 (+5.01%)
CGC   3.19 (-3.04%)
GE   158.89 (+1.27%)
DIS   111.94 (+0.32%)
AMC   4.40 (+1.85%)
PFE   26.61 (+0.19%)
PYPL   60.62 (+0.46%)
XOM   105.73 (+1.16%)
S&P 500   5,136.23 (+0.78%)
DOW   39,088.93 (+0.24%)
QQQ   445.55 (+1.49%)
AAPL   179.68 (-0.59%)
MSFT   415.27 (+0.39%)
META   501.97 (+2.42%)
GOOGL   137.79 (-0.48%)
AMZN   178.51 (+0.99%)
TSLA   202.96 (+0.53%)
NVDA   818.80 (+3.50%)
NIO   5.79 (+0.70%)
AMD   200.67 (+4.23%)
BABA   74.62 (+0.80%)
T   17.00 (+0.41%)
F   12.42 (-0.16%)
MU   95.15 (+5.01%)
CGC   3.19 (-3.04%)
GE   158.89 (+1.27%)
DIS   111.94 (+0.32%)
AMC   4.40 (+1.85%)
PFE   26.61 (+0.19%)
PYPL   60.62 (+0.46%)
XOM   105.73 (+1.16%)

CVS Health (CVS) Stock Forecast & Price Target

$73.92
-0.45 (-0.61%)
(As of 03:22 PM ET)

CVS Health Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 16 Analyst Ratings

Analysts' Consensus Price Target

$90.00
21.75% Upside
High Forecast$106.00
Average Forecast$90.00
Low Forecast$76.00
TypeCurrent Forecast
3/2/23 to 3/1/24
1 Month Ago
1/31/23 to 1/31/24
3 Months Ago
12/2/22 to 12/2/23
1 Year Ago
3/2/22 to 3/2/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
13 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$90.00$93.00$92.59$119.65
Predicted Upside21.75% Upside27.35% Upside26.44% Upside25.36% Upside
Get CVS Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CVS and its competitors with MarketBeat's FREE daily newsletter.


CVS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CVS Health Stock vs. The Competition

TypeCVS HealthRetail/Wholesale CompaniesS&P 500
Consensus Rating Score
2.88
2.43
2.48
Consensus RatingModerate BuyHoldHold
Predicted Upside21.02% Upside108.00% Upside7.23% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$88.00+13.99%
2/8/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$87.00+16.02%
2/8/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$86.00 ➝ $84.00+11.24%
12/22/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$94.00+19.56%
12/11/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$102.00 ➝ $99.00+34.11%
11/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$110.00 ➝ $100.00+43.55%
10/10/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$93.00 ➝ $80.00+11.41%
9/19/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform$81.00 ➝ $83.00+17.40%
9/12/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform$80.00+16.36%
9/1/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$85.00 ➝ $82.00+25.82%
8/17/2023Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
8/4/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$90.00 ➝ $85.00+14.34%
8/3/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$103.00 ➝ $98.00+28.26%
8/3/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$89.00 ➝ $86.00+12.55%
7/11/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$120.00 ➝ $88.00+26.86%
7/7/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$114.00 ➝ $106.00+52.43%
5/8/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$95.00 ➝ $76.00+7.53%
5/8/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$125.00 ➝ $96.00+35.82%
5/2/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$102.00 ➝ $94.00+27.22%
4/10/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
3/31/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$111.00 ➝ $104.00+39.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:41 PM ET.












CVS Price Target - Frequently Asked Questions

What is CVS Health's consensus rating and price target?

According to the issued ratings of 16 analysts in the last year, the consensus rating for CVS Health stock is Moderate Buy based on the current 2 hold ratings and 14 buy ratings for CVS. The average twelve-month price prediction for CVS Health is $90.00 with a high price target of $106.00 and a low price target of $76.00. Learn more on CVS's analyst rating history.

Do Wall Street analysts like CVS Health more than its competitors?

Analysts like CVS Health more than other Retail/Wholesale companies. The consensus rating for CVS Health is Moderate Buy while the average consensus rating for retail/wholesale companies is Hold. Learn more on how CVS compares to other companies.

Does CVS Health's stock price have much upside?

According to analysts, CVS Health's stock has a predicted upside of 23.15% based on their 12-month stock forecasts.

What analysts cover CVS Health?

CVS Health has been rated by Cantor Fitzgerald, HSBC, Leerink Partnrs, Royal Bank of Canada, SVB Leerink, and TD Cowen in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:CVS) was last updated on 3/1/2024 by MarketBeat.com Staff